• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Managed Healthcare Executive® State of Industry Survey: Which 2022 Tech, Policy Developments Will Have the Biggest Impact?

MHE PublicationMHE January 2022
Volume 32
Issue 1

Remote care technology and drug price limits garnered the most votes for having the biggest effect on the cost and delivery of U.S. healthcare.

The COVID-19 pandemic continues to scramble American healthcare, but it is already clear that telehealth and other forms of remote care are going to be lasting consequences.

That observation is reflected in results from our State of the Industry survey, which we revised this year to ask questions that look to the year ahead rather than assessing the year gone by. The survey had 100 respondents.

When we asked respondents to pick two technology developments that would have the biggest effect on the cost and development of healthcare in 2022, 66% picked remote care technologies, far outpacing the precision medicine, which was picked by 35% of the respondents, and at-home hospital care, which was picked by 29%.

We also asked about policy and political developments. It was closer race. Drug price limits (51%) and expansion of Medicare benefits (49%) finished neck and neck. Despite all the discussion, addressing social determinants of health (14%) and healthcare disparities (12%) ranked far lower.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.